Celldex Therapeutics reported $25.29M in Cash and Equivalent for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Applied Genetic Technologies AGTC:US $ 67.85M 4.92M
Aptinyx Inc APTX:US $ 100.16M 5.96M
Celldex Therapeutics CLDX:US $ 25.29M 13.85M
Cytrx CYTR:US 5.08M 1.69M
Immunogen IMGN:US $ 437.66M 41.09M
Nektar Therapeutics NKTR:US $ 25.22M 28.8M
Newlink Genetics NLNK:US $ 86.76M 8.05M
Northwest Biotherapeutics NWBO:US 15.17M 11.33M